These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27601170)

  • 1. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report.
    Ou P; Fang Z; Chen J
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e17-e18. PubMed ID: 27601170
    [No Abstract]   [Full Text] [Related]  

  • 2. [Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)].
    Vicente-Sánchez S; Menéndez Naranjo L
    Farm Hosp; 2017 Mar; 41(2):313-314. PubMed ID: 28236804
    [No Abstract]   [Full Text] [Related]  

  • 3. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Sulkowski MS; Chuang WL; Kao JH; Yang JC; Gao B; Brainard DM; Han KH; Gane E
    Clin Infect Dis; 2016 Nov; 63(9):1202-1204. PubMed ID: 27486112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
    Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L
    Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
    Weng Q; Li X; Ren H; Xie J; Pan X; Xu J; Chen N
    Oncotarget; 2017 Mar; 8(13):22299-22303. PubMed ID: 28223549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
    Oya Y; Sugawara Y; Watanabe T; Yoshimaru Y; Honda M; Hashimoto S; Yoshii D; Isono K; Hayashida S; Yamamoto H; Tanaka M; Sasaki Y; Inomata Y
    Biosci Trends; 2017 Jan; 10(6):496-499. PubMed ID: 27990005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
    Johnson SW; Davis MM; Stever LM; Priest DH
    J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
    Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
    BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
    Levitsky J; Verna EC; O'Leary JG; Bzowej NH; Moonka DK; Hyland RH; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault NA
    N Engl J Med; 2016 Nov; 375(21):2106-2108. PubMed ID: 27959735
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
    Stern R; Hametner S; Ramona AZ; Moser S; Karpi A; Laferl H; Stauber RE; Zoller HM; Maieron A; Vogel W; Graziadei I; Gschwantler M; Kozbial K; Freissmuth C; Hofer H; Ferenci P
    Am J Gastroenterol; 2016 May; 111(5):744-5. PubMed ID: 27151123
    [No Abstract]   [Full Text] [Related]  

  • 12. Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.
    Boglione L; De Nicolò A; Di Perri G; D'Avolio A
    Antivir Ther; 2019; 24(7):553-555. PubMed ID: 31502554
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
    Walsh CE; Workowski K; Terrault NA; Sax PE; Cohen A; Bowlus CL; Kim AY; Hyland RH; Han B; Wang J; Stamm LM; Brainard DM; McHutchison JG; von Drygalski A; Rhame F; Fried MW; Kouides P; Balba G; Reddy KR
    Haemophilia; 2017 Mar; 23(2):198-206. PubMed ID: 28124511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
    Keating GM
    Drugs; 2015 Apr; 75(6):675-85. PubMed ID: 25837989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
    Taramasso L; Ricci E; Celesia BM; Bonfanti P; Quirino T; Squillace N; Nicolini LA; Maggi P; Martinelli C; De Socio GV; Di Biagio A;
    Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):e76-e79. PubMed ID: 28438572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.